BR112017008827A2 - célula recombinante cho, cultura em larga escala, e, composição. - Google Patents

célula recombinante cho, cultura em larga escala, e, composição.

Info

Publication number
BR112017008827A2
BR112017008827A2 BR112017008827-4A BR112017008827A BR112017008827A2 BR 112017008827 A2 BR112017008827 A2 BR 112017008827A2 BR 112017008827 A BR112017008827 A BR 112017008827A BR 112017008827 A2 BR112017008827 A2 BR 112017008827A2
Authority
BR
Brazil
Prior art keywords
composition
large scale
recombinant cell
scale culture
cell cho
Prior art date
Application number
BR112017008827-4A
Other languages
English (en)
Inventor
Carfi Andrea
Ciferri Claudio
Hofmann Irmgard
Laux Holger
Lilja Anders
Wen Yingxia
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of BR112017008827A2 publication Critical patent/BR112017008827A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

esta invenção se refere às proteínas do citomegalovírus (cmv) adequadas para o uso em uma vacina. são aqui fornecidas células hospedeiras mamíferas, em particular as células de cho, em que a(s) sequência(s) que codifica(m) as proteínas de cmv gh, gl, pul128, pul130, pul131 (ou um fragmento que forma um complexo das mesmas) estão estavelmente integradas no genoma.
BR112017008827-4A 2014-10-31 2015-10-29 célula recombinante cho, cultura em larga escala, e, composição. BR112017008827A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14191385.5A EP3015475A1 (en) 2014-10-31 2014-10-31 Mammalian cells expressing cytomegalovirus antigens
EP14191385.5 2014-10-31
PCT/IB2015/058349 WO2016067239A1 (en) 2014-10-31 2015-10-29 Mammalian cells expressing cytomegalovirus antigens

Publications (1)

Publication Number Publication Date
BR112017008827A2 true BR112017008827A2 (pt) 2018-03-27

Family

ID=51844603

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008827-4A BR112017008827A2 (pt) 2014-10-31 2015-10-29 célula recombinante cho, cultura em larga escala, e, composição.

Country Status (19)

Country Link
US (1) US10414802B2 (pt)
EP (2) EP3015475A1 (pt)
JP (1) JP6688297B2 (pt)
CN (1) CN107075486B (pt)
AR (1) AR102464A1 (pt)
BE (3) BE1023364B1 (pt)
BR (1) BR112017008827A2 (pt)
CA (1) CA2964859C (pt)
CY (1) CY1123405T1 (pt)
DK (1) DK3212660T3 (pt)
ES (1) ES2799735T3 (pt)
HR (1) HRP20200932T1 (pt)
HU (1) HUE049356T2 (pt)
LT (1) LT3212660T (pt)
MX (1) MX2017005661A (pt)
PL (1) PL3212660T3 (pt)
PT (1) PT3212660T (pt)
SI (1) SI3212660T1 (pt)
WO (1) WO2016067239A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015103891A (ru) 2012-07-06 2016-08-27 Новартис Аг Комплексы белков цитомегаловируса
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
PT3137595T (pt) * 2014-04-29 2019-06-19 Novartis Ag Novas células de vertebrados e métodos para expressão de forma recombinante de um polipéptido de interesse
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
CA3099381A1 (en) 2018-05-04 2019-11-07 SpyBiotech Limited Vaccine composition
JP7179872B2 (ja) * 2018-12-10 2022-11-29 Ｋｍバイオロジクス株式会社 サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN117222415A (zh) * 2020-12-02 2023-12-12 Seqirus公司 多顺反子rna疫苗及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE69032809T2 (de) 1989-11-06 1999-07-08 Cell Genesys Inc Herstellung von Proteinen mittels homologer Rekombination
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
ES2716243T3 (es) * 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
RU2015103891A (ru) 2012-07-06 2016-08-27 Новартис Аг Комплексы белков цитомегаловируса
JP6392245B2 (ja) 2012-12-18 2018-09-19 ノバルティス アーゲー 遺伝子改変哺乳動物細胞における治療用タンパク質の産生
PL3083677T3 (pl) 2013-12-20 2020-03-31 Novartis Ag Nowe komórki eukariotyczne i sposoby rekombinowanej ekspresji produktu będącego przedmiotem zainteresowania
KR102288857B1 (ko) 2013-12-20 2021-08-11 노파르티스 아게 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
PT3137595T (pt) 2014-04-29 2019-06-19 Novartis Ag Novas células de vertebrados e métodos para expressão de forma recombinante de um polipéptido de interesse

Also Published As

Publication number Publication date
EP3212660B1 (en) 2020-03-25
HUE049356T2 (hu) 2020-09-28
MX2017005661A (es) 2017-06-26
CN107075486B (zh) 2021-06-22
WO2016067239A1 (en) 2016-05-06
BE1023841A1 (fr) 2017-08-09
ES2799735T3 (es) 2020-12-21
SI3212660T1 (sl) 2020-07-31
US10414802B2 (en) 2019-09-17
CN107075486A (zh) 2017-08-18
AR102464A1 (es) 2017-03-01
CY1123405T1 (el) 2021-12-31
JP2017534283A (ja) 2017-11-24
HRP20200932T1 (hr) 2020-09-18
PT3212660T (pt) 2020-06-23
BE1023840A1 (fr) 2017-08-09
PL3212660T3 (pl) 2020-10-05
EP3212660A1 (en) 2017-09-06
LT3212660T (lt) 2020-07-10
BE1023364A1 (fr) 2017-02-20
JP6688297B2 (ja) 2020-04-28
US20170362278A1 (en) 2017-12-21
EP3015475A1 (en) 2016-05-04
DK3212660T3 (da) 2020-06-15
BE1023841B1 (fr) 2017-08-10
BE1023364B1 (fr) 2017-02-20
BE1023840B1 (fr) 2017-08-10
CA2964859C (en) 2023-04-04
CA2964859A1 (en) 2016-05-06

Similar Documents

Publication Publication Date Title
BR112017008827A2 (pt) célula recombinante cho, cultura em larga escala, e, composição.
MX2021008142A (es) Metodos para cosechar cultivos de celulas de mamifero.
PE20181529A1 (es) Vacunas de acido nucleico para el virus varicela-zoster (vzv)
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
IL259595A (en) Gradual methods for the production of a recombinant adenovirus (aav) vector in a serum-free suspension cell culture system suitable for clinical use
BR112016019068A2 (pt) construto, vetor recombinante, composição farmacêutica, método de inibição de replicação viral ou expressão de uma sequência alvo em uma célula infectada com um vírus, polipeptídeo de sau cas9 recombinante, construto de sau cas9 recombinante, construto recombinante para expressão de um rna guia individual e kit
MX2017005774A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
BR112017023975A2 (pt) variantes de alfa-amilase e polinucleotídeos codificando as mesmas
BR112016030965A2 (pt) Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
BR112014024675A8 (pt) célula hospedeira recombinante, cultura celular
BR112013030396A2 (pt) polipeptídeo, polinucleotídeo, vetor, célula hospedeira, composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
MX2014015977A (es) Vacuna de adn para usarse en pacientes con cancer pancreatico.
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
BR112017003406A2 (pt) genoma de chromobacterium subtsugae
BR112015003724A2 (pt) polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína.
BR112013030824A8 (pt) Bactéria gram-positiva, ácido necleico recombinante, composição farmacêutica e vetor
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
AR089231A1 (es) Metodo de floculacion
BR112014031039A2 (pt) elementos de dna recombinante para a expressão de proteínas recombinantes em uma célula hospedeira.
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
MX2016013584A (es) Parvovirus porcino.

Legal Events

Date Code Title Description
B15N Others concerning applications: notification of judicial decision

Free format text: VARA: 25A VARA FEDERAL DO RIO DE JANEIROPROCESSO N.O 5022017-09.2019.4.02.5101) - NUP: 00408.027367/2019-14IMPETRANTE: KASZNAR LEONARDOS ADVOGADOSIMPETRADO: PRESIDENTE DO INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI?ANTE O EXPOSTO, DENEGO O MANDADO DE SEGURANCA E JULGO EXTINTO O PROCESSO SEM RESOLUCAO DO MERITO, COM FULCRO NO ARTIGO 6O, 5O, DA LEI NO 12.016/2009 C/C ARTIGO 485, VI DO CODIGO DE PROCESSO CIVIL.?

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.